Tirzepatide: How It Works, Brands and Evidence
An introduction to tirzepatide, the difference between Mounjaro and Zepbound, what clinical comparisons show and questions to discuss with a prescriber.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. Understanding the ingredient, the brand and the population in a clinical study helps avoid misleading comparisons. This introduction uses US prescribing information and published trials checked on September 9, 2026.
How tirzepatide works
Tirzepatide activates GIP and GLP-1 receptors. These pathways participate in glucose regulation; the medicine also delays gastric emptying. A description of its mechanism does not, by itself, prove that it is the best option for a particular person. See the Mounjaro prescribing information.
Mounjaro and Zepbound have different labels
Mounjaro's US indications include glucose control in people aged 10 and older with type 2 diabetes. Its August 2026 label also includes reducing major cardiovascular events in adults with type 2 diabetes at high risk. Mounjaro label
Zepbound has indications for long-term weight reduction in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside dietary and activity measures. The eligibility and dosing details belong to that product's label. Zepbound prescribing information
When reading an article or checking a prescription, ask which exact product and indication it discusses. An ingredient-level research result and an approved brand indication answer different questions.
What comparisons with semaglutide tell us
SURPASS-2 studied adults with type 2 diabetes and compared tirzepatide with semaglutide 1 mg weekly over 40 weeks. Tirzepatide produced greater average reductions in HbA1c and body weight at the tested doses. The semaglutide comparison was not its 2.4 mg obesity regimen. SURPASS-2 publication
SURMOUNT-5 instead studied adults with obesity without diabetes for 72 weeks, using higher tolerated doses of both medicines. It is relevant to a different clinical question. Read our comparison of the two trials and their limitations before treating headlines as interchangeable.
What to discuss before treatment
Tirzepatide labeling includes a boxed warning about thyroid C-cell tumors in rats, with uncertain relevance to humans, and contraindications involving medullary thyroid carcinoma or MEN2. Common adverse effects include gastrointestinal symptoms. Zepbound safety information
Discuss your medical history, other medicines, pregnancy plans, contraception and any planned anesthesia with your prescriber. Ask which symptoms require prompt care and how to contact the treatment team. The complete medication guide provides safety details that an overview cannot replace.
Prepare for the appointment
Write down the exact product being considered and your main treatment goal. Bring your medication list and ask how progress, tolerability and ongoing costs will be reviewed. Ask the pharmacist to demonstrate the device you actually receive; this article is not an injection or dose-adjustment guide.
For a practical comparison checklist, see Mounjaro vs Ozempic: brands, devices and access. For research interpretation, use the trial guide linked above. These educational pages do not recommend starting, stopping or switching a prescription.
Tags
More in GLP-1 Medications
Written By
Metabolic Science Editorial
Research and editorial content
Metabolic Science publishes educational articles with AI assistance. Our articles link to their sources and explain research limitations. They are not a substitute for care from a qualified health professional. No independent medical review is claimed.
Editorial Standards
This article follows our strict editorial guidelines. Content is prepared with AI assistance and includes source links. No independent medical review is claimed. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.